Climb Bio (CLYM) Accumulated Expenses (2020 - 2026)

Climb Bio has reported Accumulated Expenses for 7 years, with the latest figure at $984000.0 in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses fell 83.88% year-over-year to $984000.0; the trailing twelve-month figure through Mar 2026 stood at $984000.0 (down 83.88% YoY), and the FY2025 full-year result was $1.9 million, down 53.53% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $984000.0, down from $1.9 million in the prior quarter.
• The five-year high for Accumulated Expenses was $6.1 million in Q1 2025, with the low at $28000.0 in Q4 2023.
• Historically, Accumulated Expenses has averaged $3.2 million across 5 years, with a median of $2.9 million in 2024.
• Annual changes were most pronounced in 2023 — Accumulated Expenses tumbled 98.53% — and 2024, when it soared 14432.14%.
• Climb Bio's Accumulated Expenses stood at $1.9 million in 2022, then slumped by 98.53% to $28000.0 in 2023, then soared by 14432.14% to $4.1 million in 2024, then plunged by 53.53% to $1.9 million in 2025, then plunged by 47.96% to $984000.0 in 2026.
• The last three Accumulated Expenses figures came in at $984000.0 (Q1 2026), $1.9 million (Q4 2025), and $1.5 million (Q3 2025), per Business Quant data.